Search results for "ADJUVANT CHEMOTHERAPY"

showing 10 items of 53 documents

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by int…

2020

International audience; Introduction The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery.Materials and methods Data from 483 patients with ovarian cancer were retrospectively collected, from January 1, 2000 to December 31, 2016, from the FRANCOGYN database, regrouping data from 11 centers specialized in ovarian cancer treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analysis were performed to define prognostic factors of overall survival.Results The median overall sur…

Neoplasm Residualmedicine.medical_treatmentGenes BRCA2FIGO Stage IIICGenes BRCA1Platinum CompoundsCarcinoma Ovarian EpithelialCohort Studies0302 clinical medicineAscitic FluidOverall survivalPeritoneal Lavage030212 general & internal medicineOvarian NeoplasmsUnivariate analysisCytoreduction Surgical ProceduresGeneral MedicineMiddle AgedPrognosisDebulkingNeoadjuvant Therapy3. Good healthSurvival RateOncology030220 oncology & carcinogenesisFemaleTaxoidsFranceOmentumCohort studymedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAntineoplastic Agents[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsInterval debulking surgeryNeoadjuvant chemotherapyPelvis03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerOvarian cancerMedian follow-upmedicineHumansNeoplasm InvasivenessAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryRetrospective cohort studymedicine.diseaseSurgery[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMultivariate AnalysisLymph Node Excision[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieSurgeryLymphadenectomyLymph NodesOvarian cancerbusinessEuropean Journal of Surgical Oncology
researchProduct

Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial–NCT02324595): a feasibility study

2016

Background Laparoscopy has acquired an increasing role in the management of ovarian cancer. Laparoscopic cytoreduction could represent a new frontier for selected patients after neoadjuvant chemotherapy (NACT). Objective We sought to assess feasibility and early complication rate of minimally invasive (MI) interval debulking surgery (IDS) in stage III-IV epithelial ovarian cancer (EOC) patients after NACT. Study Design This is a phase II multicentric study in advanced EOC cases with clinical complete response after NACT, according to Gynecologic Cancer Intergroup and Response Evaluation Criteria In Solid Tumors criteria. Institutional review board approval was obtained and all patients sign…

Neoplasm Residualmedicine.medical_treatmentchemotherapyresidual0302 clinical medicine80 and overMedicineminimally invasive surgeryAged 80 and overOvarian Neoplasms030219 obstetrics & reproductive medicineadvanced ovarian cancerMedicine (all)Obstetrics and GynecologyCytoreduction Surgical ProceduresBowel resectionMiddle AgedDebulkinglaparoscopic cytoreductionNeoadjuvant TherapyIntestinesChemotherapy AdjuvantResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisinterval debulking surgeryFemaleMedian bodyPeritoneumOmentumneoadjuvant chemotherapyAdultmedicine.medical_specialtyOvariectomyadvanced ovarian cancer; interval debulking surgery; laparoscopic cytoreduction; minimally invasive surgery; neoadjuvant chemotherapy; quality of life; Adult; Aged; Aged 80 and over; Appendectomy; Chemotherapy Adjuvant; Fallopian Tubes; Feasibility Studies; Female; Humans; Hysterectomy; Intestines; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Residual; Omentum; Ovarian Neoplasms; Ovariectomy; Peritoneum; Cytoreduction Surgical Procedures; Laparoscopy; Medicine (all); Obstetrics and GynecologyHysterectomy03 medical and health sciencesadjuvantlocalAppendectomyHumansSurvival rateFallopian TubesAgedHysterectomybusiness.industryAdvanced ovarian cancer interval debulking surgery laparoscopic cytoreduction minimally invasive surgery neoadjuvant chemotherapy quality of life adult aged 80 and over appendectomy chemotherapy adjuvant fallopian tubes feasibility studies female humans hysterectomy intestines middle aged neoadjuvant therapy neoplasm recurrence local neoplasm residual omentum ovarian neoplasms ovariectomy peritoneum cytoreduction surgical procedures laparoscopyPerioperativeneoplasm recurrenceSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAquality of lifeFeasibility StudiesLaparoscopyLymphadenectomyNeoplasm Recurrence LocalbusinessneoplasmAmerican Journal of Obstetrics and Gynecology
researchProduct

CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective r…

2015

4007 Background: Adjuvant chemotherapy with gemcitabine (Gem) for 6 months significantly improves survival of pancreatic cancer patients. CONKO-005 was designed to evaluate an additional effect of ...

Oncology0303 health sciencesCancer Researchmedicine.medical_specialtyendocrine system diseasesAdjuvant chemotherapybusiness.industrymedicine.diseaseGemcitabine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisPancreatic cancerInternal medicinemedicineAdjuvant therapyErlotinibbusiness030304 developmental biologymedicine.drugJournal of Clinical Oncology
researchProduct

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (pCR) after primary chemotherapy.

2009

Abstract Learning Objectives After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy.Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment.Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of ou…

OncologyAdultCancer Researchmedicine.medical_specialtyTime FactorsSettore MED/06 - Oncologia MedicaReceptor ErbB-2Breast NeoplasmsVinorelbineDisease-Free SurvivalBreast cancerTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPathologicalMastectomyAgedNeoplasm StagingCisplatinStage IIIB breast cancerNeoadjuvant chemotherapyPathological responseLong-term outcomesbusiness.industryRadiotherapy DosageMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival RateRegimenTreatment OutcomeOncologyHormone receptorLymphatic MetastasisFemaleLymph Nodesbusinessmedicine.drugEpirubicinFollow-Up StudiesThe oncologist
researchProduct

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

2011

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage…

OncologyCancer ResearchLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentDiseasechemotherapyDeoxycytidinelaw.inventionCarboplatinRandomized controlled trialNon-small cell lung cancerlawCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsPostoperative radiotherapyStage (cooking)Non-Small-Cell LungSurveyVinorelbineOncologyChemotherapy AdjuvantAdjuvantmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPaclitaxelnon-small cell lung cancer; adjuvant; Survey; chemotherapyVinblastineadjuvantInternal medicinemedicineHumansLung cancerNeoplasm StagingCisplatinAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryCarcinomamedicine.diseaseGemcitabineSurgeryAdjuvant chemotherapyRadiation therapyLung NeoplasmRegimenHealth Care SurveysAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; SurveyAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; Survey; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy Adjuvant; Vinblastine; Vinorelbine; Health Care Surveys; Oncology; Pulmonary and Respiratory Medicine; Cancer ResearchRadiotherapy AdjuvantCisplatinbusiness
researchProduct

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubi…

2010

International audience; Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated whether adjuvant epirubicin (E) followed by CMF is superior to the inverse sequence in RPBC. Patients with node-negative or 1-3 node-positive RPBC (Thymidine Labeling Index > 3% or histological grade 3 or S-phase > 10% or Ki67 > 20%) were randomized to receive E (100 mg/m i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m i.v. d1 and 8, q2…

OncologyCancer ResearchSettore MED/06 - Oncologia Medicamedicine.medical_treatmentRandomized phase III study0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsCMFMedicineProspective Studies0303 health sciencesCMF; Epirubicin; Randomized phase III study; Rapidly proliferating breast cancer; Sequential adjuvant chemotherapy strategySequential adjuvant chemotherapy strategy – Epirubicin – CMF – Randomized phase III study – Rapidly proliferating breast cancerSequential adjuvant chemotherapy strategyHazard ratioMiddle Aged3. Good healthTreatment OutcomeReceptors EstrogenOncologyFluorouracilLymphatic Metastasis030220 oncology & carcinogenesisFemaleFluorouracilBreast diseaseRapidly proliferating breast cancermedicine.drugEpirubicinAdultmedicine.medical_specialtyCyclophosphamidebreast cancer epirubicinBreast NeoplasmsNeutropeniaModels Biological03 medical and health sciencesBreast cancerInternal medicineHumansCyclophosphamideAgedProportional Hazards ModelsEpirubicin030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseSurgeryMethotrexatebusinessBreast Cancer Research and Treatment
researchProduct

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.

2012

542 Background: Many ER-positive, HER2-negative breast cancer patients are treated by adjuvant chemotherapy according to current clinical guidelines. We retrospectively assessed whether the combined gene expression/ clinicopathological EndoPredict-clin (EPclin) score improved the accuracy of risk classification in addition to considering clinical guidelines. Methods: Three clinical breast cancer guidelines (National Comprehensive Cancer Center Network (NCCN), German S3 and St. Gallen 2011), and the EPclin score - assessed by quantitative RT-PCR in formalin-fixed paraffin-embedded tissue - were used to assign risk groups in 1,702 ER-positive, HER2-negative breast cancer patients from two ra…

OncologyCancer Researchmedicine.medical_specialtyBreast cancerOncologybusiness.industryAdjuvant chemotherapyInternal medicineRisk stratificationmedicineHER2 negativemedicine.diseasebusinessJournal of Clinical Oncology
researchProduct

Assessing the impact of CMF/FEC/FEC-DOC/ETC (dose-dense) adjuvant chemotherapy in dependency of positive axillary lymph nodes on survival: A retrospe…

2013

1074 Background: Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: (1) Are there differences in survival dependent on chemotherapy regimens in 0/0-3/4-10/<10 positive lymph nodes? (2) Is it possible to define a cut-off of positive lymph nodes for the use of Taxane-based and dose dense chemotherapy? Methods: This German is a multi-center [17 participating hospitals all are certified as breast cancer centers] retrospective cohort study. We included CMF (1.385), FEC (1.170), FEC-DOC (1.723), and dose-dense E…

OncologyCancer Researchmedicine.medical_specialtyChemotherapyTaxaneAxillary lymph nodesbusiness.industryAdjuvant chemotherapymedicine.medical_treatmentImproved survivalmedicine.diseasemedicine.anatomical_structureBreast cancerOncologyInternal medicineMedicinebusinessCohort studyJournal of Clinical Oncology
researchProduct

High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer

2013

Colon cancer (CC) is a leading cause of cancer mortality. Novel biomarkers are needed to identify CC patients at high risk of recurrence and those who may benefit from therapeutic intervention. The aim of this study is to investigate if miR-21 expression from RNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue sections is associated with prognosis and therapeutic outcome for patients with CC. The expression of miR-21 was measured by quantitative reverse transcriptase-polymerase chain reaction in a Japanese cohort (stage I-IV, n = 156) and a German cohort (stage II, n = 145). High miR-21 expression in tumors was associated with poor survival in both the stage II/III Japanese (p …

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerAdjuvant chemotherapybusiness.industryMicrosatellite instabilitymedicine.diseaseOncologyInternal medicinemicroRNACohortImmunologymedicineAdjuvant therapyBiomarker (medicine)Stage (cooking)businessInternational Journal of Cancer
researchProduct